BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 10,000 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $90.32, for a total transaction of $903,200.00. Following the sale, the chief executive officer now owns 235,894 shares of the company’s stock, valued at approximately $21,305,946.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Jean Jacques Bienaime also recently made the following trade(s):
- On Saturday, December 29th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $89.61, for a total transaction of $896,100.00.
- On Friday, December 29th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $89.75, for a total transaction of $1,795,000.00.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at $89.98 on Friday. BioMarin Pharmaceutical Inc. has a 12 month low of $80.10 and a 12 month high of $100.51. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. The firm has a market cap of $15,800.00, a PE ratio of -108.41 and a beta of 1.81.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The business had revenue of $334.18 million during the quarter, compared to analysts’ expectations of $347.38 million. During the same quarter in the previous year, the company earned $0.02 EPS. The business’s revenue was up 19.4% on a year-over-year basis. equities analysts expect that BioMarin Pharmaceutical Inc. will post -0.64 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the business. Toronto Dominion Bank increased its holdings in BioMarin Pharmaceutical by 12.9% in the 2nd quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 243 shares during the period. Commerce Bank bought a new position in BioMarin Pharmaceutical in the 3rd quarter valued at about $209,000. Cambridge Investment Research Advisors Inc. bought a new position in BioMarin Pharmaceutical in the 2nd quarter valued at about $213,000. Teacher Retirement System of Texas bought a new position in BioMarin Pharmaceutical in the 3rd quarter valued at about $220,000. Finally, First Republic Investment Management Inc. bought a new position in BioMarin Pharmaceutical in the 3rd quarter valued at about $220,000. Institutional investors and hedge funds own 99.02% of the company’s stock.
A number of analysts have recently issued reports on the stock. Leerink Swann restated an “outperform” rating and set a $142.00 target price (up previously from $136.00) on shares of BioMarin Pharmaceutical in a research note on Thursday, October 19th. SunTrust Banks set a $115.00 target price on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Thursday, October 19th. Piper Jaffray Companies restated a “buy” rating and set a $113.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, September 21st. Wedbush upgraded shares of BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $110.00 target price for the company in a research note on Thursday, December 14th. Finally, BidaskClub upgraded shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 16th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $112.32.
ILLEGAL ACTIVITY NOTICE: This report was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://ledgergazette.com/2018/01/12/insider-selling-biomarin-pharmaceutical-inc-bmrn-ceo-sells-903200-00-in-stock.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.